Sarcura

Sarcura is a private, pre-revenue platform technology company focused on transforming cell therapy manufacturing. The company is developing a closed, automated system that uses semiconductor-based microfluidics and AI-driven control to produce cell therapies with greater quality, scalability, and cost-efficiency than current manual processes. Backed by seed funding and grants, Sarcura targets the critical bottleneck in the rapidly growing cell therapy market, aiming to make these life-saving treatments more accessible. Its leadership team combines expertise in business, science, and engineering to execute this ambitious vision.

Autonomous, miniaturized device platform using semiconductor chip technology, microfluidics, and machine intelligence for closed-system cell therapy manufacturing.

Sarcura competes with established players like Lonza and Miltenyi Biotec who offer automated, closed-system platforms, as well as other startups innovating in cell therapy manufacturing. Its key differentiator is the deep miniaturization and cell-level control enabled by semiconductor technology, a unique approach that could offer superior precision and scalability if successfully commercialized.